Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net.
Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber. | May 5, 2023
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed. | May 4, 2023
/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an.
/PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a medical technology company driven to.